Table 1. Key randomized phase III trials of first-line chemotherapy for metastatic pancreatic cancer.
| Author/Year | Treatment | Progression-Free survival (months) | Overall survival (months) | 12 month overall survival (%) |
|---|---|---|---|---|
| Burris et al. 1997 | Gemcitabine | 2.33* | 5.65* | 18 |
| 5-fluorouracil | 0.92 | 4.41 | 2 | |
| Moore et al. 2007 | Gemcitabine + erlotinib | 3.55* | 6.24* | 23* |
| Gemcitabine | 3.75 | 5.91 | 17 | |
| Cunningham et al. 2009 | Gemcitabine + capecitabine | 5.3* | 7.1 | 24.3 |
| Gemcitabine | 3.8 | 6.2 | 22 | |
| Conroy et al. 2011 | FOLFIRINOX | 6.4* | 11.1* | 48.4 |
| Gemcitabine | 3.3 | 6.8 | 20.6 | |
| Von Hoff et al. 2013 | Gemcitabine + nab-paclitaxel | 5.5* | 8.5* | 35* |
| Gemcitabine | 3.7 | 6.7 | 22 |
*Statistically significant with p<0.05